There seems to be some confusion regarding what the current NICE guidelines are, so I looked them up!
The current "Summary of national guidance for lipid management" (last updated 8 December 2022), can be downloaded from here:
https://www.england.nhs.uk/aac/publication/summary-of-national-guidance-for-lipid-management/
Two things in particular can be noted:
1) They still rely on QRISK3, and I gave the link for that previously (
https://qrisk.org/ ). The only lipid information QRISK3 uses is "Cholesterol/HDL ratio".
2) The goal of statin treatment is repeatedly described as "reduction of non-HDL-C > 40% from baseline". No specific figure is given.
So the experts at NICE have decided-- on the basis of reviewing the relevant research-- that, in relation to lipids, the key risk trigger is the ratio of total cholesterol to HDL. And that, in terms of reducing risk, the key thing is reducing non-HDL cholesterol, but there is no magic number.
If you know of actual research, done within the past year, demonstrating that NICE is wrong on these points, please do post links!